Weekly subcutaneous treatments of semaglutide, originally developed to treat diabetes, are sold and marketed under the brand name Wegovy.

Researchers shared long-term follow-up data from the Colchicine-PCI trial, which compared colchicine administration before PCI with a placebo.

Anjali Owens, MD, discussed the past, present and future of hypertrophic cardiomyopathy care in the United States. "What we are aiming to do is develop a minimum standard for assessments of patients with HCM so they are getting properly diagnosed and managed," she explained. 

Valentin Fuster, MD, PhD, one of the world’s most prominent cardiologists, said "it is now our responsibility to ensure these treatments are widely available and used by the medical community.”

The Hypertrophic Cardiomyopathy Association (HCMA) has helped guide and advance HCM care not only for patients, but also for hospitals and physicians. 

COVID-19 opened the eyes of many cardiology researchers that infections may promote inflammation in atherosclerotic plaques, leading to cardiac events.

Matthew Martinez, MD, detailed the many ways HCM care management is changing during an exclusive interview at ASE 2023.

The updated recommendations from the American College of Cardiology and American Heart Association cover a variety of topics, including patient communication, follow-up imaging, nutritional supplements and more.